Matthew W. Foehr
2021 - Ligand Pharmaceuticals
In 2021, Matthew W. Foehr earned a total compensation of $5.3M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 52% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $259,467 |
---|---|
Option Awards | $1,226,357 |
Salary | $518,933 |
Stock Awards | $3,146,844 |
Other | $130,603 |
Total | $5,282,204 |
Foehr received $3.1M in stock awards, accounting for 60% of the total pay in 2021.
Foehr also received $259.5K in non-equity incentive plan, $1.2M in option awards, $518.9K in salary and $130.6K in other compensation.
Rankings
In 2021, Matthew W. Foehr's compensation ranked 2,451st out of 12,415 executives tracked by ExecPay. In other words, Foehr earned more than 80.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,451 | 80th |
Manufacturing | 973 | 82nd |
Chemicals And Allied Products | 373 | 84th |
Drugs | 325 | 85th |
Pharmaceutical Preparations | 214 | 86th |
Foehr's colleagues
We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2021.